Havas Health and BrightInsight Form Partnership
Havas Health announced an exclusive strategic partnership with BrightInsight, a digital platform for biopharma. The alliance aims to address patient adherence and persistence issues in the pharmaceutical industry, a problem estimated to be worth over $500 billion.
- This exclusive agreement designates Havas Health as BrightInsight's sole global agency partner, creating a combined offering of strategy, creative, and a compliant digital platform. - A key objective of the alliance is to bridge the gap between a patient receiving a prescription and that treatment being effective in a real-world setting. - BrightInsight's technology has demonstrated the ability to improve patient adherence to their prescribed therapy by four percentage points over traditional patient support programs. - The partnership is a component of Havas Health's "Converged" strategy, which focuses on blending human insight with advanced technology. - Jeff Hoffman, Chief Development Officer for the Havas Health Network, noted that this provides clients with a "pre-vetted, regulatory-ready engine" to make a patient's brand experience more meaningful. - The BrightInsight platform is built with pre-existing functionalities that can meet 60-80% of what clients typically require, which can speed up the time to market for digital health tools by 6 to 24 months. - Havas Health has a history of developing award-winning campaigns, such as the "ParkinSex" initiative for the American Parkinson Disease Association, which earned "Best in Show" at the 2023 Medical Marketing + Media awards. - BrightInsight's platform is designed for global scalability and is ready for deployment in over 64 countries with localization into more than 25 languages.